Regeneron Pharmaceuticals Inc (NASDAQ:REGN)
| 544.01 Delayed Data As of May 27 |  -1.20 / -0.22%Today’s Change | 271.37 Today|||52-Week Range 583.54 | +44.88% Year-to-Date |
Latest REGN News | Press Releases
| Sanofi to Sell Its 20.6% Stake in Regeneron, but Keep Their Collaboration Intact May 26 / MotleyFool.com - Paid Partner Content | Why Sorrento Therapeutics Stock Is on Fire Today May 18 / MotleyFool.com - Paid Partner Content |
| Here's Why Editas Could Beat Intellia to a CRISPR Therapy May 22 / MotleyFool.com - Paid Partner Content | Why Gilead's Remdesivir Might Not Be the Mega-Moneymaker Some Think It Will Be May 17 / MotleyFool.com - Paid Partner Content |
| Here's Why Sorrento Therapeutics Dropped 16.6% Today May 19 / MotleyFool.com - Paid Partner Content |
Today’s Trading
| Previous close | 545.21 |
| Today’s open | 538.70 |
| Day’s range | 522.02 - 555.53 |
| Volume | 5,902,647 |
| Average volume (3 months) | 1,334,057 |
| Market cap | $64.1B |
Data as of 4:26pm ET, 05/27/2020
Growth & Valuation
| Earnings growth (last year) | -14.46% |
| Earnings growth (this year) | +8.73% |
| Earnings growth (next 5 years) | +14.00% |
| Revenue growth (last year) | +17.18% |
| P/E ratio | 27.3 |
| Price/Sales | 5.47 |
| Price/Book | 5.67 |
Competitors
Data as of 4:00pm ET, 05/27/2020
Financials
| Next reporting date | July 30, 2020 |
| EPS forecast (this quarter) | $5.89 |
| Annual revenue (last year) | $7.9B |
| Annual profit (last year) | $2.1B |
| Net profit margin | 26.91% |
Profile
Sector Health Technology |
Industry Biotechnology |
No executives to display |
Corporate headquarters Tarrytown, New York |
Forecasts
